BDR Pharma launches generic Palbociclib for breast cancer treatment

BDR Pharma recently launched a new generic drug Palbociclib with the brand name Bdpalbo for the advanced treatment of metastatic breast cancer in India. The drug will be made available in three strengths i.e. – 125 mg, 100 mg and 75 mg capsules priced at Rs 3,150 for 75 mg; Rs 3,600 for 100 mg and Rs 4,464 for 125 mg, a company statement informed.

It said that Palbociclib (Bdpalbo) is an oral inhibitor of CDKs 4 and 6, which are the key regulators of the cell cycle that trigger cellular progression. It is indicated for the treatment of adult patients with Hormone Receptor-positive (HR+), Human Epidermal growth factor Receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in post-menopausal women or in men; or as a combination therapy with Fulvestrant in patients with disease progression following endocrine therapy.

As per clinical data on Paloma 3 trial, among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, Palbociclib combined with Fulvestrant resulted in longer progression-free survival than Fulvestrant alone, the statement added.